Emphasis on Application (Therapeutic, Research, and Diagnostics); Source (Human, Goat Milk, and Others); Dosage Form (Lyophilized and Liquid); Region/Country.
The antithrombin market is expected to witness a CAGR of around 5% during the forecast period (2021–2027). Antithrombin is a small glycoprotein produced by the liver that inactivates many enzymes of the coagulation system by neutralizing the enzymatic activity of thrombin. Antithrombin deficiency can lead to thromboembolism, a condition in which a clot develops in a blood vessel, this can severely affect the functioning of other organs like the kidneys, brain, gastrointestinal tract, and lungs. Moreover, this can create complications during & after surgeries, and during pregnancy, untreated antithrombin deficiency is associated with up to a 50% risk of venous thromboembolism (VTE) and a relative risk of pregnancy loss of 2.1 with a 5-fold increase in stillbirths. Furthermore, according to the Centers for Disease Control and Prevention (CDC), in 2020, a total of 3,613,647 births were registered in the U.S.
Some of the major companies operating in the antithrombin market include F Grifols S.A., Octapharma AG, LFB USA Inc., CSL Limited, Takeda Pharmaceuticals, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, Lee Biosolutions Inc., BDI Pharma Inc.
Insights Presented in the Report
“Amongst Application, the therapeutic category accounted for the majority share in the market in 2020”
Based on application, the antithrombin market is segmented into therapeutic, research, and diagnostics. the therapeutic category is anticipated to witness a considerable growth rate during the forecast period. This is mainly due to the increasing prevalence of blood clotting diseases and increases in the therapeutic and diagnostic usage of Antithrombin. Additionally, the rising cases of cardiac disorders such as heart failure, high blood pressure, and coronary artery diseases due to blood clotting, are also contributing to the growth of the market. For instance, as per the data published by the American Society of Hematology 900,000 people in the United States develop blood clots yearly, and they are accountable for approximately 100,000 casualties each year.
“Amongst Source, the goat milk category is expected to witness the highest CAGR during the forecast period”
Based on source, the antithrombin market is segmented into human, goat milk, and others. The goat milk category is anticipated to witness a significant growth rate during the forecast period. Owing to its high capacity of producing antithrombin protein, the F.D.A. also approved the goats used to make the drug, the first such animals cleared under guidelines the agency to regulate the use of transgenic animals in the nation’s drug and food supply. Additionally, antithrombin III deficiency is a blood-clotting disease that main reason for Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). For instance, according to the NCBI, the incidence of pulmonary embolism (PE) ranges from 39 to 115 per 100 000 population annually; for DVT, the incidence ranges from 53 to 162 per 100,000 people.
“Amongst Dosage form, the lyophilized category is expected to witness a considerable growth rate during the forecast period”
Based on dosage form, the antithrombin market is categorized into lyophilized and liquid. The lyophilized category captured a significant share of the market and is anticipated to witness a considerable growth rate during the forecast period. This is mainly due to its wide application in the treatment of thrombin deficiency and coronary heart diseases (CAD). Moreover, lyophilized antithrombin is also used to treat venous thromboembolism (VTE) and peripheral artery diseases (PAD) which is an underdiagnosed and serious, yet preventable medical condition that can cause disability and death.
“North America to witness significant growth during the forecast period”
For a better understanding of the market, the report provides a detailed analysis of major regions and countries including North America (U.S., Canada, Rest of North America); Europe (Germany, U.K., France, Spain, Italy, Rest of Europe); Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific) and Rest of World. North America accounted for a significant market share during the forecast period. This is mainly due to the prevalence of antithrombin deficiency diseases such as Peripheral Artery Disease (PAD), heart-related diseases obesity, AT deficiency, etc. Moreover, the presence of major pharmaceutical & drug manufacturing companies and well-settled healthcare infrastructure are also contributing to the growth of this market. for instance, according to the data published by the U.S. Department of Health & Human Services in 2018, antithrombin deficiency is expected to occur in about 1 in 2,000 people across the globe.
Reasons to buy this report:
Customization Options:
The antithrombin market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.
1. Market Introduction
2. Research Methodology Or Assumption
3. Market Synopsis
4. Executive Summary
5. Antithrombin Market Covid-19 Impact
6. Antithrombin Market Revenue, 2019-2027f
7. Market Insights By Application
8. Market Insights By Source
9. Market Insights By Dosage Form
10. Market Insights By Region
11. Antithrombin Market Dynamics
12. Antithrombin Market Opportunities
13. Antithrombin Market Trends
14. Legal & Regulatory Framework
15. Demand And Supply Side Analysis
16. Value Chain Analysis
17. Competitive Scenario
18. Company Profiled
19. Disclaimer
Research Methodology for the Antithrombin market Analysis (2021-2027)
Analyzing the historical market, estimating the current market, and forecasting the future market of the antithrombin market were the three major steps undertaken to create and analyze the adoption of the antithrombin market in major regions globally. Exhaustive secondary research was conducted to collect the historical market numbers and estimate the current market size. Secondly, to validate these insights, numerous findings and assumptions were taken into consideration. Moreover, exhaustive primary interviews were also conducted, with industry experts across the value chain of the antithrombin market. Post assumption and validation of market numbers through primary interviews, we employed a top-down/bottom-up approach to forecasting the complete market size. Thereafter, market breakdown and data triangulation methods were adopted to estimate and analyze the market size of segments and sub-segments of the industry pertains to. Detailed methodology is explained below:
Seek More Details About Research Methodology
Analysis of Historical Market Size
Step 1: In-Depth Study of Secondary Sources:
Detail secondary study was conducted to obtain the historical market size of the antithrombin market through company internal sources such as annual reports & financial statements, performance presentations, press releases, etc., and external sources including journals, news & articles, government publications, competitor publications, sector reports, third-party database, and other credible publications.
Step 2: Market Segmentation:
After obtaining the historical market size of the antithrombin market, we conducted a detailed secondary analysis to gather historical market insights and share for different segments & sub-segments for major regions. Major segments are included in the report as application, source, and dosage form. Further country-level analyses were conducted to evaluate the overall adoption of testing models in that region.
Step 3: Factor Analysis:
After acquiring the historical market size of different segments and sub-segments, we conducted a detailed factor analysis to estimate the current market size of the antithrombin market. Further, we conducted factor analysis using dependent and independent variables such as various application, source, and dosage form of the antithrombin market. A thorough analysis was conducted for demand and supply-side scenarios considering top partnerships, mergers and acquisitions, and business expansion, in the antithrombin market sector across the globe.
Current Market Size Estimate & Forecast
Current Market Sizing: Based on actionable insights from the above 3 steps, we arrived at the current market size, key players in the antithrombin market, and market shares of the segments. All the required percentage shares split, and market breakdowns were determined using the above-mentioned secondary approach and were verified through primary interviews.
Estimation & Forecasting: For market estimation and forecast, weights were assigned to different factors including drivers & trends, restraints, and opportunities available for the stakeholders. After analyzing these factors, relevant forecasting techniques i.e., the top-down/bottom-up approach were applied to arrive at the market forecast for 2027 for different segments and sub-segments across the major markets globally. The research methodology adopted to estimate the market size encompasses:
Market Size and Share Validation
Primary Research: In-depth interviews were conducted with the Key Opinion Leaders (KOLs) including Top Level Executives (CXO/VPs, Sales Head, Marketing Head, Operational Head, Regional Head, Country Head, etc.) across major regions. Primary research findings were then summarized, and statistical analysis was performed to prove the stated hypothesis. Inputs from primary research were consolidated with secondary findings, hence turning information into actionable insights.
Split of Primary Participants in Different Regions
Market Engineering
The data triangulation technique was employed to complete the overall market estimation and to arrive at precise statistical numbers for each segment and sub-segment of the antithrombin market. Data was split into several segments & sub-segments post studying various parameters and trends in the areas of application, source, and dosage form in the antithrombin market.
The main objective of the antithrombin market Study
The current & future market trends of the antithrombin market were pinpointed in the study. Investors can gain strategic insights to base their discretion for investments on the qualitative and quantitative analysis performed in the study. Current and future market trends determined the overall attractiveness of the market at a regional level, providing a platform for the industrial participant to exploit the untapped market to benefit from a first-mover advantage. Other quantitative goals of the studies include:
Customers who bought this item also bought
Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
Emphasis on Disease Type (Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, And Others); Pathogen Type (Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and Others); Drug Class (Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others); and Region/Country
October 8, 2024
